Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma

• Niels Weinhold,
• Desiree Kirn,
• Anja Seckinger,
• Thomas Hielscher,
• Martin Granzow,
• Uta Bertsch,
• Gerlinde Egerer,
• Hans Salwender,
• Igor W. Blau,
• Katja Weisel,
• Jens Hillengass,
• Marc S. Raab,
• Dirk Hose,
• Hartmut Goldschmidt,
• Anna Jauch

Affiliations

Niels Weinhold

Department of Internal Medicine V, University of Heidelberg, Germany;Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA

Desiree Kirn

Institute of Human Genetics, University of Heidelberg, Germany

Anja Seckinger

Department of Internal Medicine V, University of Heidelberg, Germany

Thomas Hielscher

Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany

Martin Granzow

Institute of Human Genetics, University of Heidelberg, Germany

Uta Bertsch

Department of Internal Medicine V, University of Heidelberg, Germany

Gerlinde Egerer

Department of Internal Medicine V, University of Heidelberg, Germany

Hans Salwender

Department of Hematology and Oncology, Asklepios Klinik Altona, Hamburg, Germany

Igor W. Blau

Department of Medicine III, Charité Campus Benjamin Franklin, Berlin, Germany

Katja Weisel

Department of Hematology, Oncology and Immunology, University of Tübingen, Germany

Jens Hillengass

Department of Internal Medicine V, University of Heidelberg, Germany

Marc S. Raab

Department of Internal Medicine V, University of Heidelberg, Germany

Dirk Hose

Department of Internal Medicine V, University of Heidelberg, Germany;National Center for Tumor Diseases, Heidelberg, Germany

Hartmut Goldschmidt

Department of Internal Medicine V, University of Heidelberg, Germany;National Center for Tumor Diseases, Heidelberg, Germany

Anna Jauch

Institute of Human Genetics, University of Heidelberg, Germany